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Summary 
We have investigated whether sequence 67 to 74  shared by B chains of rheumatoid arthritis 
(RA)-associated HLA-DR molecules imparts a specific pattern of peptide binding. The peptide 
binding specificity of the RA-associated molecules, DRBI*0401,  DRBI*0404,  and the closely 
related, RA nonassociated DRBI*0402 was, therefore, determined using designer peptide libraries. 
The effect of single key residues was tested with site-directed mutants of DRBI*0401. The results 
have demonstrated striking differences between RA-linked and unlinked DR allotypes in selecting 
the portion of peptides that interacts with the 67-74 area. Most differences were associated with 
a single amino acid exchange at position 71 of the DR ~ chain, and affected the charge of residues 
potentially contacting position 71. The observed binding patterns permitted an accurate prediction 
of natural protein derived peptide sequences that bind selectively to RA-associated DR molecules. 
Thus, the 67-74 region, in particular position 71, induces changes of binding specificity that 
correlate with  the genetic linkage of RA susceptibility.  These findings should facilitate the 
identification of autoantigenic peptides involved in the pathogenesis of RA. 
S 
usceptibility to rheumatoid arthritis (tLA) t is specifically 
associated  with the class II MHC  alleles DRBI*0401, 
DRBI*0404,  and DRBI "0101 (1, 2). Interestingly, the DR/~/ 
chains encoded by these genes possess  a "shared epitope" 
formed by a short stretch of amino acids (at positions 67-74) 
that is highly conserved among RA-associated molecules (3, 
4). Since DRB*0402, a closely related molecule not associated 
with  RA,  differs  from  the  RA-linked  DRBI*0401  and 
DRBI*0404  molecules only in the 67-74 region (at posi- 
tions 67,  70,  and 71), this part of the molecule is likely to 
be critical for disease  association. 
Polymorphic MHC residues can affect the immune system 
in at least two different ways. First, they can alter the specificity 
of the peptide binding site (5) and thus control the array of 
antigenic peptides presented to T cells. Second, they influence 
the selection of TCR specificities  during the development 
of the T cell repertoire (6, 7). The role of the 67-74 region 
in RA association can be explained on a similar basis, since 
autoimmunity is considered to underlie the pathogenesis of 
RA.  Thus,  RA-associated DR allotypes, because of their 
1 Abbreviations used in this paper: NMP, N-methyl-2 pyrrolidone; RA, 
rheumatoid arthritis; RT, room temperature; p, peptide position. 
similar peptide binding specificity, may be the ones capable 
of presenting certain autoantigenic peptides critical for the 
development of disease. Alternatively, this region may be re- 
quired for the selection of TCtL capable of recognizing the 
pathogenic self peptide(s). 
In an attempt to gain insight into the mechanism of RA 
association,  we have studied the influence of the 67-74 re- 
gion on the peptide binding specificity of RA associated and 
nonassociated DR  molecules, using  site-directed mutants 
of class  II  molecules, designer peptide libraries,  and high 
throughput binding assays (8, 9). The results reported here 
demonstrate a striking correlation between binding specificity 
and disease association, depending largely on a single amino 
acid position 71 of the B chain. 
Materials and Methods 
Preparation  of HLA-DR  Molecules 
DR. molecules were isolated from human lymphoblastoid cell 
lines BSM (DRBI*0401), 2046 (DRBI*0402), and MT (DRBI* 
0404), and L cell transfectants as described (10). The following L 
cell transfectants were used: L 565H.1 (DRBI*0401) and site- 
directed mutants L 286.10 where K was exchanged to E at position 
71 of DRBI*0401 (0401/K71E) and L 335.2 where K was exchanged 
to tL at position 71 of DRBI*0401 (0401/K71R) (11). Site-directed 
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extension method, and the mutants were sequenced to confirm the 
presence of the mutation and absence of misincorporation. 
Peptide Synthesis 
The selectively randomized peptide libraries,  the set of peptide 
position 1 (pl) anchored designer peptides and peptides with nat- 
ural protein-derived sequences  were synthesized with a multiple 
peptide synthesizer (model 396; Advanced ChemTech, Louisville, 
KY) using Fmoc chemistry and solid phase  synthesis  (12). 
Selectively Randomized Peptide  Libraries.  19 selectively randomized 
peptide libraries  GZAAXAXAAX  were synthesized where each 
one carries  a different natural amino acid residue (except Cys) at 
relative p1 (Z), p4, p6, and p9 were randomized (X) in all sub- 
libraries and p2, p3, p5, p7, and p8 were occupied by Ala residues 
(A). The synthesis was performed as follows: 3 g resin was equally 
distributed into  19 reaction vessels preceding the synthesis  of a 
random peptide position. Each Fmoc natural amino acid residue 
(except  Cys) was individually coupled using quadruple coupling 
procedures. After the synthesis of the Ala spacer and before the 
next random position, the resin was recovered from the reaction 
vessels, mixed, and redistributed. Mixing was omitted after the 
synthesis  of the Z position. 
Pl-anchored Designer Peptides.  A set of pl-anchored designer pep- 
tides was synthesized as described (9). It consists of the basic pep- 
tide GFKAAAAAAA-NH2 where all natural amino acid residues 
(except Cys) were single substituted at p3-p7, and F corresponds 
to pl.  The sequence of the basic peptide is the result of several 
optimization experiments with the purpose of reaching an ICs0 
value within a given binding assay, which allows one to measure 
100-fold decreases and increases of the IC50 after the introduction 
of anchor and inhibitory residues, respectively. The peptides were 
analyzed by analytical reverse-phase HPLC and the peptides used 
in this study were routinely >175% pure. 
Biotinylation  of Peptides.  Peptides  were  specifically  NHz- 
terminal biotinylated using the Advanced ChemTech 396 robotic 
system as follows: 50 mg of resin with NH2-terminal deprotected 
peptides  were  suspended  and  washed  at  least  three  times  in 
N-methyl-2-pyrrolidone (NMP). A two-fold excess of biotin-XX- 
n-hydroxysuccinimide over the free NH2 termini of the resin in 1 
ml NMP was added, and the suspension  was incubated for 30 min 
with agitation. The biotinylation step was repeated once. Subse- 
quently, the resin was washed three times with NMP, five times 
with methanol, and dried in vacuum. The biotinylated peptides 
were deprotected and cleaved from the resin with 95% TFA, 2.5% 
thioanisol,  1.25%  distilled  water, and  1.25% phenol. 
DR-Peptide  Binding  Assays 
Peptide side chain scanning was performed either with a high- 
flux DR-peptide competition assay as described (8, 9), or with an 
ELISA-based  high-flux competition assay, especially developed to 
detect peptide binding to DR molecules isolated from L cell trans- 
fectants. The ELISA-based  assay was performed as follows.  Pep- 
tides were dissolved in DMSO at a concentration of 5 raM, diluted 
1:4 in PBS, and transferred into the (A)-row wells of 96-well plates 
(dilution plates).  90 #1 of DMSO/PBS (1:4) was added to the (B)- 
(F) row wells of the dilution plates and the peptides were simul- 
taneously diluted by serially transferring 10 #1 aliquots from row 
(A) to row (B)-(F).  10/~1 of each well was transferred to the corre- 
sponding wells of a second set of 96-well plates (binding plates). 
10 ~1 of NH2-terminal biotinylated peptide in PBS (0.5-5 #M) was 
added to each well of the binding plate.  Subsequently, 30 #1 of 
affinity-purified DR4 antigens (~0.2-1/zg protein) in 5/zl volume 
and 25/zl binding buffer (2% NP40, 2 mM PMSF, 2 mM EDTA, 
20/zg/ml each of soybean trypsin inhibitor, antipain, pepstatin, 
leupeptin, and chymostatin, 0.15 M NaC1, and 50-100 mM citrate 
phosphate buffer,  pH 7) was added to each well of the binding 
plates  and incubated for t>24 h at room temperature (RT). The 
ELISA plates were prepared as follows. 50 #1 per well of 10 #g/ml 
anti-DR mAb (L243) was used to coat the plates. The wells were 
washed twice with distilled water, blocked with 200 #1 blocking 
buffer (PBS with 0.05% Tween 20, 1 mM EDTA, 0.25% BSA frac- 
tion V, and 0.05% NAN3) for at least 2 h at RT and washed twice 
with distilled water. 25/xl PBS/0.15% Tween 20 was added to each 
well of the binding plates.  Subsequently,  50 t~l of each well was 
transferred to the corresponding wells of the ELISA plates and in- 
cubated for >/2 h at RT. After washing three times with PBS/O.05% 
Tween 20, 50/~1 Streptavidin-alkaline-phosphatase  in PBS/0.05% 
Tween 20 was added to each well and incubated for 30 min at RT. 
The plates were then washed twice with distilled water, once with 
PBS/0.05% Tween 20, and twice again with distilled water. 200 
/~1 per well of 1 mg/ml p-nitrophenylphosphate in 50 mM NaCO3 
and 50 mM MgCI2 was added and incubated for ~3 h at 37~ 
The amount of substrate hydrolyzed was  assessed with a spec- 
trophotometer (405 nm). The radiolabeled (conventional high-flux 
assay [9]) or biotinylated (ELISA-based assay) peptides used in this 
study were either flu hemagglutinin  peptide  HA  307-319  (for 
DRBI*0401  only)  or  the  "universal  DR4"  (UD4)  peptide, 
YPKFVKQNTLKAA, designed to bind to all DR4 allotypes with 
high affinity. 
Modeling  of the DRB'0402  Binding Site 
The  DRBI*0402  peptide  model  was  constructed  from  the 
DRBI*0101-HA peptide crystal structure model (13) by substituting 
the DRBI*0402 amino acid residues at positions 9, 11, 13, 26, 28, 
30, 31, 37,  67, 70, 71, and 86 on the DRBI*0101 ~-subunit and 
replacing  the residue  side  chains  in  the  HA peptide with  Ac- 
FKAWATAAA-NH2 such that the Phe in the modeled peptide oc- 
cupied the Tyr site in the HA peptide. The coordinates for the pep- 
tide backbone were not altered from the crystallographic positions. 
This model was minimized to a 0.1 A root mean square  (RMS) 
energy gradient using the AMBER 4.0 molecular mechanics and 
dynamics software package (14) with the all atom force field (15) 
and a distance-dependent dielectric model. Minimization was fol- 
lowed by 150 picoseconds of molecular dynamics at 300 K during 
which the entire ligand and the altered amino acid residues on the 
protein were allowed  to move according to tohe classical laws of 
motion. An additional minimization to a 0.01 ARMS energy gra- 
dient yielded the final structure. The refined model was displayed 
using the GRASP software package  (16). 
Results 
Similar Residues at the Main Anchor Positions Are Required 
for  Peptide Binding  to  DRBI*040I,  and  DRBI*0404,  and 
DRB1*0402.  The R.A-associated DR4 subtypes, DRBI*0401, 
and DRBI*0404, differ only at amino acid positions 67, 70, 
and 71 from the nonassociated subtype DRBI*0402  (Table 
1).  As  shown by a model of the DRBI*0402/DRA*0101 
peptide binding site (Fig.  1), this difference is located such 
that it may not alter the specificity of DR4 subtypes for an- 
chor residues at pl and p6, although it is predicted to affect 
residues at p4, p5, and p7. We tested this hypothesis by corn- 
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Used in this Study 
DIL~ residues  at position 
HLA-DR  67  70  71  86 
DRBI*0401  L  Q  K  G 
DRBI*0404  -  *  -  IL  V 
DRB 1"0402  I  D  E  V 
DRB1*0401/K71R*  -  -  R  - 
DRB1*0401/K71ES  -  -  E  - 
* Sequence identity with DRBI*0401. 
* Site-directed mutants of Lys to Arg (K71R), and 
Lys to Glu (K71E) at position 71 of DRBI*0401. 
paring  the  peptide binding  specificity of DRBI*0404  and 
DRBI*0402. To determine the pl anchor specificity, we used 
selectively randomized peptide libraries with relative anchor 
positions 4, 6, and 9 randomized and pl fixed to I of 19 amino 
acid residues as described in Materials and Methods.  By this 
method,  the influence of a particular  peptide  sequence on 
binding is minimized, and thus, the effect of a single residue 
at pl  can be tested in a manner largely independent  of the 
remaining sequence. The results defining pl anchor specificity 
are shown in Fig.  2.  It is clear that Ile, Leu, Met, Phe, and 
Val can serve as pl  anchor residues for both DR  allotypes. 
This  pattern  is  almost  identical  with  the pl  specificity of 
DRBI*0401  and  DRBI*0101  (17).  The  difference is  that 
residues  Trp and  Tyr can  serve as  anchors  for DRBI*0401 
and  DRBI*0101,  but  they  are  not  accepted  by  either 
DRBI*0404 or DRBI*0402.  This correlates with a Gly to 
Val exchange at position 86 of the corresponding DR~ chains 
that is known to alter the hydrophobic pocket accommodating 
the  pl  anchor  (13). 
We then compared the effect of different side chains at p6 
on peptide binding  to  the three DR4  subtypes.  These ex- 
periments were performed using a set of pl-anchored designer 
peptides where all natural amino acid residues (except Cys) 
were single substituted at relative p6 as described in Materials 
and Methods.  As shown in Fig. 3, a  and b, the same p6 an- 
chor residues, Set, Thr, Asn, and Val, were identified for all 
three subtypes. We observed only one significant difference 
between DR.BI*0402 and the two RA-associated subtypes, 
namely that Arg at p6 did not influence binding to the former, 
but inhibited binding to the latter (see below). We also per- 
formed anchor shifting experiments, and demonstrated iden- 
tical spacing of the two major anchor positions (pl and p6) 
for the three DR allotypes (Fig. 3 c). These findings suggest 
a  similar  overall  conformation  of peptides  bound  to  RA- 
associated  and  nonassociated  DR4  subtypes. 
Position 71 of the DRfl  Chain Induces Major Differences of 
Peptide Binding Specificity between  DR4 Subtypes.  The overall 
similar  conformation of peptides bound to the three DR4 
subtypes permitted us to systematically scan p3 to p7 for the 
Figure 1.  The DRBl*0402 peptide modal viewed from above the 
binding site (a), and from the side of position 1 of the bound peptide 
(b). The protein Ca backbone of the binding site is shown schematically 
as a tube diagram (cyan) with the o~-subunit helix above the B-subunit 
helix (a), and the c~-subunit helix left and B-subunit helix right (b). The 
amino acid substitutions distinguishing DRBl*0402 from the RA-linked 
DR4 molecules  at position 67, 70, and 71, respectively,  are clustered near 
the center of the ~-subunit helix (yellow). Note that the center of the 
B-subunit helix is adjacent to the middle of the bound peptide (a) and 
it bulges up above  the bound peptide (b), offering  sites of interaction with 
side chains branching out of the Ca atoms (green) at p4, pS, and p7 of 
the peptide (p6, when occupied by a small anchor residue such as Thr, 
is buried in the binding site, and thus not seen). The backbone of the 
bound peptide (Ac-FKAWATAA-NH2)  is shown as spheres (blue,  N; red, 
O; white, carbonyl C; green, Cc~). 
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Similar specificity (a and b) and spacing (c) of the p6 anchor 
for peptide binding to DRB1*0401,  DRB1 *0404, and DRBl*0402. The 
effect of 19 amino acid side chains on binding to DRBI*0404  (a), and 
Table  2.  ResuloofSideChain  Scanning onDRBl*0402 
G  F  K  X  X  X  X  X  A  A 
pl  p2  p3  p4  p5  p6  p7  p8  p9 
A  0  0  0  0  0 
D  -0.9*  -2.3#  -2.3  -1.0  -2.1 
E  -1.1  -2.3  -1.3  -2.5  -1.4 
F  -0.3  +0.3  -0.3  -1.2  +0.9 
G  -0.9  -0.8  -1.4  -1.1  -1.3 
H  -0.2  +1.2  -0.2  -1.0  +0.5 
I  +0.5  +0.1  -0.1  -0.3  +0.5 
K  -0.6  +0.1  +0.3  -2.5  0 
L  +0.2  -0.6  -0.1  -1.0  +1.0 
M  +0.6  +0.6  -0.1  -1.2  +0.8 
N  -0.5  -0.4  -1.2  +1.0  +0.6 
P  -0.7  -1.3  +0.1  -0.4  -1.0 
Q  -0.6  -0.4  -0.2  -0.8  +1.1 
R  -0.4  +1.0  +0.5  -0.2  +1.7 
S  -0.4  -0.9  -0.2  +0.9  -0.4 
T  -0.6  -0.5  -0.1  +1.5  +0.1 
V  0  -0.6  0  +1.0  +0.2 
W  -0.6  +1.6  -0.6  -0.8  +1.4 
Y  0  -0.5  -0.3  -1.2  +0.9 
* Data are expressed as rehtive binding, i.e., the logarithm of the reciprocal 
of Ala-normalized ICs0 values (log [ICs0-Ah/ICs0-~,v]).  Side chain scan- 
ning was performed using a set of pl-anchored designer peptides where 
all amino acid residues,  except Cys, were single substituted at relative 
positions 3-7. GFKAAAAAAA-NH2  was the basic peptide where F cor- 
responds to relative position 1. The average ICs0 of the basic peptide was 
6 #M. The radiolabeled UD4 was used as a reference peptide in the high- 
flux DR-peptide competition assay. 
The DRBI*0402  scanning  values that differ from both DRBI*0401 
(at least 100-fold) and DRBI*0404 (at least 10-fold) are in boldface. Sig- 
nificant differences between DRBl*0402 and the RA-associated subtypes 
were confirmed by several independent experiments using different sets 
of peptides. 
induction of differences in binding specificity. As shown by 
the model in Fig.  1,  this part of the peptide is likely to be 
influenced by the 67-74 area of the binding site. The results 
of side chain  scanning  for DRBI*0402  are summarized  in 
Table 2. Similar scanning was performed for DRBI*0401  (9), 
DRBI*0402 (b) was determined at relative anchor position 6. P6 anchor 
shifting (c) was performed to test spacing between pl and p6. Data were 
determined by side chain scanning using GFKAAAAAAA  based, single- 
substituted,  pl-anchored peptides, and compared with side chain scanning 
results with DRB1*0401 using YASAAAAAA  based peptides (Y = pl) (9). 
The data in (a-c) are expressed as relative binding, derived as follows: ICs0 
values were normalized by dividing them with ICs0 values of Ala substi- 
tutions. The logarithm of reciprocal, normalized ICso values was plotted 
[log (ICs0-Ah/ICs0-~p)]. Data are derived from the high-flux DR-peptide 
competition assay, using radiolabeled HA 307-319 (DRBI* 0401) and UD4 
(DRB1*0402  and DRB1*0404)  as reference peptides. 
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Figure  4.  Differences in peptide 
binding specificity of R.A-associated 
and nonassociated  DR4 subtypes, 
and the effect of position B 71. The 
effect of the charged  residues  (in 
boldface) in Table 2 is shown for i04, 
p5,  and p6.  Relative binding data 
were derived as in Fig. 3, and plotted 
in comparison  to binding data  of 
DRB1 "0401 as the baseline. GFK- 
AAAAAAA  was used as basic pep- 
tide for all DR subtypes  and mu- 
tants. Data were either derived from 
the DR-peptide competition assay, 
using radiolabeled UD4 as reference 
peptide,  or from the ELISA-based 
DR-peptide competition assay (DR 
molecules from wild-type and mu- 
tant  transfectants),  using biotiny- 
lated UD4 as a reference peptide. 
and DRBI*0404 (data not shown). Significant  differences be- 
tween DRBI*0402 and the two RA-associated subtypes were 
observed in the effect of charged residues. Most of these effects 
were seen at p4, but some were also identified at p5-p7. The 
nature of these charge effects is shown in Fig. 4. The most 
striking  difference is that  peptides with positively charged 
residues, Lys or Arg, at p4 or p6 bind 100-1,000-fold better 
to DRBI*0402 than to DRBI*0401 and DRBI*0404. Con- 
versely,  peptides with negative residues, Asp or Glu,  at p4 
or p5 bind  100-500-fold less well to DRBI*0402  than  to 
DRBI*0401,  and '~50-fold less well than to DRBI*0404. 
A site-directed mutant molecule that differs from DRBI*0401 
only in a single Lys to Glu exchange at position 71 of the 
/~  chain  exhibits  a  binding  specificity  similar  to  that  of 
DRBI*0402 (Fig. 4). Thus, exchange of the basic Lys to the 
acidic Glu at position  71 seems to account alone for most 
major differences in binding specificity between RA-associated 
and nonassociated DR4 allotypes. We have also observed a 
smaller  but  significant  difference  between  the  two  RA- 
associated molecules. Namely, peptides with a negative res- 
idue  (Asp  or  Glu)  at  p4  bound  20-50-fold  better  to 
DRBI*0401 than to DRBI*0404. Mutating position 71 Lys 
of DRBI*0401  to the Arg found in DRBI*0404 resulted 
in decreased binding of these peptides to levels comparable 
to the binding by DRBI*0404 (Fig.  4). Thus,  position 71 
of the/~  chain is responsible also for the minor  difference 
between the two RA-linked allotypes. We found three addi- 
tional significant  differences between DRBI*0402 and the 
other two DR4 subtypes, i.e.,  peptides with Trp at p4 or 
p7, or Arg at p7 bound to the former 10-100-fold better than 
to the latter (Table 2).  Since these effects could not be un- 
equivocally associated with position 71 (data not shown), ad- 
ditional amino acid differences between these molecules (see 
in Table  1) may be responsible for them. 
Prediction of Natural Protein Sequences Selectively Binding  to 
RA-associated  DR4  Molecules.  To  address  the  biological 
significance of the observed differences in binding specificity, 
we asked whether  it is possible to predict  protein regions 
selectively binding to RA-associated DR4 subtypes. For this 
purpose, we selected four proteins implicated in the patho- 
genesis  of arthritis  (18-21).  Of 3,518  nonapeptide  frames 
screened using the selection criteria in Fig. 5, only 14 flames 
were predicted to bind to DRBI*0401 and failed to bind to 
DRBI*0402. In the selection, we used a relatively low binding 
score for DRBI*0401 (corresponding to a low affinity cut- 
off; 9) to indude most flames, potentially binding  to this 
molecule. To evaluate our prediction, all peptides with scores 
>--2 (9) and pl anchor residues used by all DR4 subtypes (see 
above) were synthesized and tested for binding to DRBI*0401. 
25 of them, with a high binding affinity to DRBI*0401 com- 
parable to that of HA 307-319 (+  fivefold, data not shown), 
were selected for comparative binding  studies (peptide  se- 
quences listed in Table 3). Eight of them were predicted to 
bind selectively to RA-associated DR4 subtypes according 
to the rules in Fig.  5,  that  is,  they were expected to bind 
poorly to DRBI*0402. As shown in Fig. 6 a, these 8 pep- 
tides did bind poorly to DRBI*0402, whereas 15 of 17 pep- 
tides predicted to be nonselective DR4 binders were found 
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peptide frames 
(9-mers) 
CRITERIA  OF  SELECTION 
"0401 binding" 
1.  [0401 peptide score 2 2] 
2.  pl-anchors used by all DR4 alleles 
[no Tyr or Trp] 
"0402 non binders" 
3.  [Asp or Glu at p4 and/or Asp at p5] 
14 
peptide |tames 
(9-mers) 
Figure  5.  Criteria used to iden- 
tify mtural protein-derived peptides 
that  selectively  bind  to  KA- 
associated  DR4 molecules. The pep- 
tide score is the sum of the effects 
exerted by side chains at each posi- 
tion,  in  comparison  to  Ala,  on 
binding of the peptide. This value 
is derived from side chain scanning 
data for DRBI*IM01, and correlates 
with binding affinity (9). The 3518 
nonamers  screened were from car- 
tilage link protein, procoUagen  alpha 
1  (II)  chain  precursor,  hsp65  of 
Mycobacterium tuberculosis,  and 
fillagrin (up to residue 1243). 
Table  3.  High Affinity DRB1 *0401-binding Natural Peptides with Predicted  Selectivity  for RA-associated DR4 Molecules 
Predicted  selective 
No.  Selected peptides  binding 
123456789* 
1.  Link  61-73  AKFYRDPTAFGSGS  + 
2.  Link  170-182  YNLNFHEAQQAAL  _I 
3.  Link  249-261  DVFAFTSNFNGRF  - 
4.  Link  268-280  TKLTYDEAVQAAL  + 
5.  Collagen 13-25  LTLLVAAVLRAQG  - 
6.  Collagen 1165-1177  DPLQYMRADQAAG  - 
7.  Collagen 1168-1180  QYMRADQAAGGLR  + 
8.  Collagen 1306-1318  MTFLRLLSTEGSQ  - 
9.  Collagen 1307-1319  TFLRLLSTEGSQN  - 
10.  Collagen  1340-1352  KALL I QGSNDVE I  - 
11.  Collagen 1350-1362  VE I RAEGNSRFTY  + 
12.  hsp65  181-193  FGLQLELTEGMRF  + 
13.  hsp65  189-201  EGMRFDKGY I SGY  + 
14.  hsp65  216-228  PY I LLVSSKVSTV  - 
15.  hsp65  284-296  KAMLQDMA I LTGG  + 
16.  hsp65  509-521  GLFLTTEAVVADK  - 
17.  Fillagrin 9-21  Y I LFAHLVNKVH I  - 
18.  Fillagrin 34-46  FA I  I NLFNEYSKK  - 
19.  Fillagrin 491-503  GSFLYQVSTHEQS  - 
20.  Fillagrin 492-504  SFLYQVSTHEQSE  - 
21.  Fillagrin 644-656  SSFSQDRDSQAQS  + 
22.  Fil]agrin 815-827  GSFLYQVSTHEQS  - 
23.  Fillagrin 816-828  SFLYQVSTHEQSE  - 
24.  Fillagrin 1139-1151  GSF I YQVSTHEQS  - 
25.  Fillagrin  1140-1152  SF I YQVSTHEQSS  - 
* Numbers indicate the position and the pl-frames of the selected peptides. 
# Peptides were selected according to criteria 1 and 2 in Fig. 5, and shown experimentally to have affinities  _+ fivefold that of HA 307-319. Peptide 
sequences  were derived from the proteins described in Fig. 5. 
S Cys residues  were replaced  by Ala residues  in all peptides. 
el Predicted to bind selectively to RA-associated DR4  subtypes (Fig. 5). 
I Predicted to be nonselective DR4 binders according to Fig. 5. 
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Figure 6.  Binding  of the selected DRBl*0401-binding 
peptides (shown in Table 3) to R.A-associated  DRBI*0404 
and nonassociated  DRB1 *0402 molecules (a), and the effect 
of removing  negative  peptide residues  on DRB1*0402 binding 
(b). (a) The relative  binding data, derived  from reciprocal ICs0 
values, were based on the binding values of the UD4 peptide 
(ICs0 ~  0.1 #M) which was set as 1. Arrows indicate pep- 
tides predicted to bind selectively  to RA-associated  DR4 sub- 
types, i.e., to bind poorly to DRB1 *0402. Peptide numbers 
are defined  in Table 3. Data were derived  from the DR-peptide 
competition assay,  using radiolabeled  UD4 as a reference  pep- 
tide. (b) In the mutant peptides, the negative residues Asp 
and Glu were exchanged  to Ala at p4 (and at p5 of peptides 
4 and 11, because of slight negative  effects  of E and G at pS). 
Binding data were derived from reverse ICs0 values from the 
ELISA-based  DR-peptide competition  with biotinylated  UD4 
as reference peptide. 
to  be  nonselective.  Moreover,  exchange of the critical p4 
residues to Ala in the peptides predicted to bind selectively 
to RA-associated  subtypes increased their binding af~nity 
~100-fold for the RA nonassociated molecule DRBI*0402 
(Fig. 6 b). These data confirm the role of position 71 of the 
DR3 chain in determining peptide binding specificity, and 
demonstrate the potential applicability of the concept in the 
identification of autoantigenic peptides. 
Discussion 
The study presented here, together with our previous work 
(9,  17,  22,  23),  establishes the rules of peptide binding to 
DR molecules associated with susceptibility to RA. There 
are three major anchor and inhibitory positions involved in 
binding, at pl, p4, and p6 of the pl-frame. At pl, a hydro- 
phobic anchor is required for binding to all DR molecules 
tested so far. However, there is a difference in fine specificity 
at this position, namely Trp and Tyr that can serve as anchors 
for DRBI*0401 and DRBI*0101, are not accepted by either 
DI~Bl*0404 or DRBI*0402. This difference correlates with 
a Gly/Val dimorphism at position 86 of DR3 chains. Since 
position 86 forms part of a hydrophobic pocket accommo- 
dating the pl anchor (13),  the position 86 dimorphism was 
expected to have a direct effect on peptide binding. Clearly, 
this dimorphism  cannot  influence R.A-linkage,  since both 
residues occur in RA-associated  (as well as nonassociated) 
molecules. However, if one assumes that a common set of 
peptides has to be presented by different DR molecules for 
RA induction, such a set cannot comprise peptides with Trp 
or Tyr at pl. Another important anchor at p6 has been previ- 
ously shown to influence allele specificity of peptide binding 
(23). This anchor is shared by all DR4 molecules tested, Jr- 
1853  Hammer  et al. respective of RA association.  Although the p6 specificity does 
not correlate with genetic linkage,  the preponderance of DR4 
subtypes in RA indicates that the DR4-specific p6 anchor, 
Thr,  Ser, Ash, or Val, is probably an important  component 
of disease-inducing  peptides. 
The critical peptide position for RA association has turned 
out to be p4. The p4 anchor appeared pseudo-monomorphic 
in previous studies, because Met was the preferred residue 
for three different DR alleles, although allele-dependent  differ- 
ences in fine specificity have been noted (22,  23).  The use 
of a set of pl-anchored  designer peptides in a recent study 
(9) and in the present experiments has revealed a striking differ- 
ence in the effect of charged residues at p4. Namely, a nega- 
tive charge is accepted and a positive charge is not accepted 
by the RA-associated DR4 subtypes, and the opposite is the 
case for the nonassociated DRBI*0402. A similar charge effect 
operates also at p5 (Asp). Substitution experiments on nat- 
ural protein-derived peptide sequences have further confirmed 
these results. Most peptides with negative charges at p4 bind 
poorly to the nonassociated DRBI*0402. However, they lose 
their selective binding to RA-associated DR4 subtypes when 
Asp or Glu is replaced by Ala at p4. Thus, a negative charge 
at p4 and/or p5 may be a distinctive feature of the putative 
pathogenic peptides involved in RA. Only two exceptions 
were noted where charge  effects do  not  explain  the  poor 
binding to DRBI*0402 (peptides 10 and 16 in Fig. 6 a). This 
may be due to peptide sequence-specific parameters, not de- 
tected by the side chain  scanni.ng. 
As shown by modeling, p4 seems to anchor in the vicinity 
of the RA-associated 67-74 region of the/3 chain.  In sup- 
port of this is our result that a Lys to Glu exchange at posi- 
tion 71 can change most RA-associated binding features into 
the RA nonassociated pattern.  Our data also imply a minor 
role for residues 67 and 70 in peptide binding, which, how- 
ever, remains to be investigated in detail. Thus,  the residue 
at  position  71  seems to  exert  a  major  effect on  the  RA- 
associated binding  pattern. 
Our results do not directly address the association of RA 
with DRBI*0101.  Although  this molecule also shares  the 
67-74 sequence with RA-associated DR4 subtypes, it differs 
from the latter at several amino acid positions within the pep- 
tide binding site. Considering also that the DRBI*0101 linkage 
has a partially different ethnic distribution (24), it is reason- 
able to assume that the disease involves a different set of pep- 
tides, although the same charge effect may apply around p4. 
Altogether, the results strongly support the hypothesis that 
selective binding of peptides is the major mechanism under- 
lying MHC association of RA.  It  should be pointed out, 
however, that our data do not necessarily argue against a pos- 
sible role of the 67-74 region in T  cell repertoire selection. 
In fact, the important  residues of this region are located in 
the center of the ot helix that protrudes above the plane of 
the binding site, and is therefore highly likely to be contacted 
by TCRs. In general, the selection of complementary TCRs 
by MHC molecules may be a prerequisite for the recognition 
of all antigens presented by the selecting molecule in the pe- 
riphery, including the antigens involved in disease. However, 
the specific question of whether or not the 67-74 region is 
the only structure capable of selecting pathogenic T cells in- 
volved in RA is not  addressed by our studies. 
The results presented herein provide a sufficiently accurate 
basis for the prediction of T cell epitopes of any protein im- 
plicated as a potential autoantigen in RA. The peptides cor- 
responding to such sequences can then be tested directly for 
their role as autoantigens. 
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